Zimmer Biomet Holdings (NYSE:ZBH) has been experiencing mixed performances of late. On one hand, UBS has classified the company as a low-ranking quant stock, experiencing underperformance when compared against its competitors on several occasions. On the other hand, noteworthy occurrences such as landing a deal with Arnold Schwarzenegger, acting as Chief Movement Officer, have been quite influential. Questions about ZBHβs earnings quality remain, despite the companyβs positive Q3 2024 Earnings and accusations of underperforming the healthcare sector. Mixed evaluations continue; the company's shares underwent changes as some such as Sumitomo Mitsui Trust, Janney Montgomery Scott, and River Global Investors increased their stakes, while Principal Financial Group, Victory Capital Management, and Costello Asset Management reduced their holdings. Zimmer Biomet's Q3 2024 results outdid predictions, and they remain committed to launching innovative solutions as proven by the Z1 Hip System launch. The company also experienced some internal alterations with the appointment of David DeMartino as Senior Vice President of Investor Relations.
Zimmer Biomet Holdings ZBH News Analytics from Thu, 08 Feb 2024 08:00:00 GMT to Sat, 16 Nov 2024 15:11:58 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor -2